Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Marburgvirus Infections (Marburg Hemorrhagic Fever) – Drugs In Development, 2024 report and make more profitable business decisions.
Marburg hemorrhagic fever is a rare, acute infectious disease that affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain, and weight loss.
The Marburgvirus Infections (Marburg Hemorrhagic Fever) drugs in development market research report provide comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Marburgvirus Infections (Marburg Hemorrhagic Fever) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 44 molecules, with 35 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Marburgvirus Infections (Marburg Hemorrhagic Fever) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Marburgvirus Infections (Marburg Hemorrhagic Fever) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbVacc IncAlbert B. Sabin Vaccine Institute Inc
ANP Technologies Inc
Auro Vaccines LLC
Blue Water Biotech Inc
Collaborations Pharmaceuticals Inc
Dominari Holdings Inc
Drexel University
Emergent BioSolutions Inc
Emergex Vaccines Holding Ltd
Flow Pharma Inc
Fox Chase Chemical Diversity Center Inc
Gamaleya Federal Research Center of Epidemiology and Microbiology
Georgia State University
GeoVax Labs Inc
Globavir Biosciences Inc
Helix Biogen Institute
Imperial College London
Integrated BioTherapeutics Inc
International AIDS Vaccine Initiative Inc
Intervir Therapeutics
Mapp Biopharmaceutical Inc
Microbiotix Inc
Moderna Inc
Phoenix Biotechnology Inc
ReVacc Biotech
Rodos BioTarget GmbH
Selva Therapeutics Inc
Soligenix Inc
TFF Pharmaceuticals Inc
The National Institute of Allergy and Infectious Diseases
University of Iowa
University of Nebraska
University of Oxford
Uvax Bio LLC
Veru Inc
Table of Contents
Table
Figures
Frequently asked questions